Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Berg Aaron
2. Date of Event Requiring Statement (Month/Day/Year)
03/11/2019
3. Issuer Name and Ticker or Trading Symbol
AMARIN CORP PLC\UK [AMRN]
(Last)
(First)
(Middle)
C/O AMARIN PHARMA, INC., 1430 ROUTE 206
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
CHIEF COMMERCIAL OFFICER
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

BEDMINSTER, NJ 07921
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Ordinary Shares (1) 36,351
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2)   (3)   (4) Ordinary Shares (1) 29,000 $ 0 D  
Restricted Stock Units (2)   (5)   (4) Ordinary Shares (1) 78,000 $ 0 D  
Restricted Stock Units (2)   (6)   (4) Ordinary Shares (1) 38,200 $ 0 D  
Stock Option (Right to Buy)   (7) 12/02/2022 Ordinary Shares (1) 43,253 $ 12.6 D  
Stock Option (Right to Buy)   (8) 02/02/2025 Ordinary Shares (1) 3,906 $ 1.02 D  
Stock Option (Right to Buy)   (9) 07/06/2025 Ordinary Shares (1) 219,562 $ 2.5 D  
Stock Option (Right to Buy)   (10) 02/01/2026 Ordinary Shares (1) 36,458 $ 1.4 D  
Stock Option (Right to Buy)   (11) 02/01/2027 Ordinary Shares (1) 69,270 $ 2.95 D  
Stock Option (Right to Buy)   (12) 05/01/2028 Ordinary Shares (1) 117,000 $ 2.8 D  
Stock Option (Right to Buy)   (13) 02/01/2029 Ordinary Shares (1) 53,500 $ 16.87 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Berg Aaron
C/O AMARIN PHARMA, INC.
1430 ROUTE 206
BEDMINSTER, NJ 07921
      CHIEF COMMERCIAL OFFICER  

Signatures

/s/ Joseph Kennedy, by power of attorney 03/20/2019
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
(2) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.
(3) On February 1, 2017, the Reporting Person was granted 87,000 RSUs under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2018, January 31, 2019, and January 31, 2020.
(4) Not applicable.
(5) On May 1, 2018, the Reporting Person was granted 78,000 RSUs under the Plan. These RSUs vest in three equal installments on each of May 1, 2019, May 1, 2020, and May 1, 2021.
(6) On February 1, 2019, the Reporting Person was granted 38,200 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2020, January 31, 2021, and January 31, 2022.
(7) On December 3, 2012, the Reporting Person was granted an option to purchase 75,000 Ordinary Shares under the Plan. The shares subject to this option are fully vested as of the date hereof.
(8) On February 2, 2015, the Reporting Person was granted an option to purchase 93,750 Ordinary Shares under the Plan. The shares subject to this option are fully vested as of the date hereof.
(9) On July 6, 2015, the Reporting Person was granted an option to purchase 400,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments on the last day of each month that began on July 31, 2015.
(10) On February 1, 2016, the Reporting Person was granted an option to purchase 125,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments on the last day of each month that began on February 28, 2016.
(11) On February 1, 2017, the Reporting Person was granted an option to purchase 133,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments on the last day of each month that began on February 28, 2017.
(12) On May 1, 2018, the Reporting Person was granted an option to purchase 117,000 Ordinary Shares under the Plan. The shares subject to this option shall vest as follows: 25% of the total number of underlying shares shall vest on May 1, 2019, and the remaining 75% of the underlying shares shall vest ratably over the subsequent 36 months.
(13) On February 1, 2019, the Reporting Person was granted an option to purchase 53,500 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 16 equal quarterly installments starting on May 15, 2019.
 
Remarks:
Pursuant to Amarin's expanded commercial efforts, the company's Board of Directors has deemed Aaron Berg to be an executive officer in accordance with Section 16.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.